Business Context and Reporting Period
This Form 8-K was filed by EyePoint Pharmaceuticals, Inc. on October 7, 2022. The report addresses the termination of a material definitive agreement with Imprimis Rx, LLC, a subsidiary of Harrow Health, Inc., regarding the commercial alliance for the product DEXYCU.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the contractual termination and its operational implications.
Material Changes
- Agreement Termination: The Commercial Alliance Agreement with ImprimisRx, originally effective August 1, 2020, will terminate effective January 1, 2023.
- Cause: The termination was triggered by the 2023 Medicare Hospital Outpatient Prospective Payment System (OPPS) and ASC Payment System Proposed Rule, which did not extend the pass-through payment period for DEXYCU beyond December 31, 2022.
- Operational Adjustments: ImprimisRx will continue sales and marketing support through Q4 2022 at effort levels consistent with the January through June 2022 period.
- Sales Targets: Required minimum quarterly sales levels for Q4 2022 have been decreased based on DEXYCU unit demand.
Guidance, Outlook, and Risks
Management commentary indicates that the termination is a direct response to regulatory changes by the Center for Medicare & Medicaid Services (CMS). The primary risk identified is the loss of the pass-through payment status for DEXYCU after December 31, 2022, which necessitated the end of the commercial alliance. The full text of the Termination Agreement is expected to be filed as an exhibit to the Annual Report on Form 10-K for the period ending December 31, 2022.
Investor Verification Checklist
- Verify the specific financial impact of the decreased minimum quarterly sales levels for Q4 2022.
- Confirm the Company's strategy for commercializing DEXYCU post-January 1, 2023, following the termination of the ImprimisRx alliance.
- Review the upcoming Form 10-K for the full text of the Termination Agreement and any associated financial adjustments.
- Assess the long-term implications of the CMS OPPS and ASC Payment System rules on DEXYCU's reimbursement and market access.